ISSN: 3033-3326

Review Article

Journal of Chemotherapy and Cancer Research

Zynteglo - A Review

Simhachalam Gurugubelli[1*], Sai giridhar Gundepalli[2], Ujwala Koduru[3], Swetha Pydi[4] and Arvind Kunadi[5]

[1]*Memorial health system, Mississippi, USA*
[2]*Cheyenne Regional medical center, Wyoming, USA*
[3]*Mclaren Lansing, Michigan, USA*
[4]*Memorial health system, Mississippi, USA*
[5]*Mclaren Flint, Michigan, USA*

[*]**Corresponding author**
Simhachalam Gurugubelli, Memorial health system, Mississippi, USA.

Received: May 02, 2024; **Accepted:** May 15, 2024; **Published:** May 20, 2024

ABSTRACT
Beta thalassemia is a hereditary hemoglobin disorder characterized by reduced or absent synthesis of the beta globin chains of hemoglobin. It affects millions worldwide, posing significant morbidity and mortality challenges, particularly in the pediatric population. This review explores the epidemiology, pathophysiology, and current treatment landscape of beta thalassemia, focusing on Zynteglo (Lentiglobin), a promising gene therapy approved for transfusion-dependent beta thalassemia.

Mechanistic insights into Zynteglo's action and eligibility criteria for potential recipients are discussed, offering insights into its clinical implications.

Keywords: Beta Thalassemia, Zynteglo, Lentiglobin, Gene Therapy, Hemoglobin, Transfusion- Dependent, Pathophysiology, Eligibility Criteria, Mechanism of Action

Introduction

Beta thalassemia is a group of autosomal recessive hemoglobinopathies, posing significant challenges to healthcare systems globally. It is characterized by decreased or absent synthesis of the beta globin chains of hemoglobin. Beta thalassemia manifests across a spectrum of severity, from asymptomatic carriers to life-threatening transfusion-dependent forms. The disorder's prevalence varies widely across different geographical regions, with higher frequencies observed in the Mediterranean, Middle East, South Asia, and Southeast Asia. In the United States, beta thalassemia mainly affects individuals with generational ties to endemic regions, although prevalence rates are comparatively lower compared to Asian countries, there has been approximately 7.5% increase in the prevalence in the past 50 years [1]. Despite advances in supportive care, such as regular blood transfusions and iron chelation therapy, the management of beta thalassemia remains challenging, with significant morbidity and mortality implications.

Beta thalassemia arises due to mutations in the HBB gene, leading to impaired synthesis of beta globin chains causing imbalance in the production of hemoglobin subunits [2]. This imbalance disrupts the formation of functional hemoglobin tetramers, impairing oxygen transport and leading to ineffective erythropoiesis, chronic hemolytic anemia, and compensatory erythroid expansion in the bone marrow [2,3].

The clinical manifestations of beta thalassemia range from mild anemia and fatigue to severe transfusion-dependent anemia, hepatosplenomegaly, growth retardation, and skeletal abnormalities. Long-term complications include iron overload, endocrine dysfunction, cardiac complications, and impaired quality of life [4,5].

The burden of beta thalassemia extends beyond the individual, impacting families, communities, and healthcare systems worldwide. The chronic nature of the disease requires lifelong management, causing economic and psychosocial challenges on affected individuals and their caregivers [6,7]. The financial stress associated with frequent blood transfusions, iron chelation therapy, and supportive care measures further worsens the socioeconomic disparities faced by patients and families [8].

Citation: Simhachalam Gurugubelli, Sai giridhar Gundepalli, Ujwala Koduru, Swetha Pydi, Arvind Kunadi. Zynteglo - A Review. J Chem Can Res. 2024. 2(2): 1-6. DOI: doi.org/10.61440/JCCR.2024.v2.12

In recent years, innovative therapeutic modalities, including gene therapy, have emerged to address the underlying genetic defect and decrease the disease burden. Zynteglo (Lentiglobin), developed by Bluebird Bio, represents a FDA approved gene therapy for transfusion-dependent beta thalassemia. This transformative approach involves ex vivo modification of autologous hematopoietic stem cells with a lentiviral vector encoding a functional beta-globin gene. The modified cells are then reinfused into the patient, with the aim of restoring hemoglobin production and reducing or eliminating the need for chronic transfusions.

Zynteglo therapy promises as a curative treatment for transfusion-dependent beta thalassemia, with potential for prolonged remission and improved quality of life. Promising results seen in clinical trials have demonstrated sustained reductions in transfusion requirements, increased hemoglobin levels, and improvements in patient-reported outcomes [9,10]. However, challenges remain, including the need for long-term follow-up to assess the durability of therapeutic responses, optimize treatment protocols, and address safety concerns associated with gene therapy [11].

This review aims to provide a comprehensive overview of beta thalassemia, including its epidemiology, pathophysiology, current treatment landscape, and the mechanistic insights and clinical implications of Zynteglo therapy. By elucidating the multifaceted nature of beta thalassemia and the potential of emerging therapeutic modalities, this review seeks to inform clinicians, researchers, and policymakers about the evolving landscape of beta thalassemia management and the role of gene therapy in transforming the treatment paradigm for this debilitating disorder.

Epidemiology of Beta Thalassemia

Beta thalassemia is a hereditary hemoglobin disorder. It is a major public health concern worldwide, particularly in areas with high incidence of consanguinity. Factors such as population migration, genetic heterogeneity and social practices influence beta thalassemia epidemiology. In order to effectively manage and allocate resources, it is necessary to understand distribution and prevalence patterns of beta thalassemia.

The prevalence of beta thalassemia varies significantly from one geographic region to another, with higher incidences observed in certain ethnic populations. Historically, beta thalassemia was endemic to the Mediterranean basin, giving it the name "Mediterranean anemia." Countries such as Italy, Greece, Cyprus, and Turkey have reported high carrier frequencies, with rates exceeding 10% in certain communities. Similarly, in the Middle East, countries like Iran, Iraq, and Saudi Arabia exhibit high prevalence rates of beta thalassemia due to consanguineous marriages and endogamous mating practices [12].

South Asia, including countries like India, Pakistan, Bangladesh, and Sri Lanka, also bears a substantial burden of beta thalassemia. The prevalence rates vary within and between these countries, influenced by factors such as regional genetic diversity and migration patterns. Southeast Asia, particularly Thailand, Indonesia, and the Philippines, also reports significant numbers of individuals affected by beta thalassemia, although prevalence rates may be lower compared to other regions [13].

In the United States, beta thalassemia is relatively rare compared to endemic regions but remains a significant health concern, particularly in communities with ancestral ties to high-prevalence areas [7,14]. The prevalence of beta thalassemia carriers varies among different ethnic groups, with individuals of Mediterranean, Middle Eastern, South Asian, and Southeast Asian descent being at higher risk.

Globally, it is estimated that over 300,000 infants are born annually with severe forms of thalassemia, including beta thalassemia major and intermedia [8,15]. The World Health Organization (WHO) recognizes beta thalassemia as a major public health issue, particularly in regions with limited access to healthcare resources and genetic counseling services. The economic burden of beta thalassemia is substantial, encompassing direct medical costs associated with disease management, as well as indirect costs related to productivity loss and caregiver burden.

Efforts to mitigate the burden of beta thalassemia include population-based screening programs, premarital and prenatal genetic counseling, and advancements in disease management strategies. However, disparities in access to healthcare and genetic services persist, particularly in low- and middle- income countries where resources are limited [16]. Addressing the multifaceted challenges posed by beta thalassemia requires a comprehensive approach, encompassing public health interventions, research initiatives, and advocacy efforts aimed at raising awareness and improving access to care for affected individuals and families.

Pathophysiology of Beta Thalassemia [17-20]:

Mutations in HBB gene, which encodes the globin subunit of hemoglobin, are responsible for beta thalassemia. These mutations affect the production of functional beta globin chains, which leads to ineffective erythropoiesis, chronic hematological anemia and secondary complications such as iron overload, bone deformation or organ damage.

The degree of beta globin chain deficiency determines the severity of Beta thalassemia. Severe anemia, requiring regular blood transfusions to sustain life, occurs in patients with beta thalassemia major. In contrast, those with beta-thalassemia intermedia may not require transfusions but still experience significant anemia and complications such as splenomegaly and skeletal abnormalities.

Complications of beta-thalassemia arise due to chronic anemia, ineffective erythropoiesis, and iron overload from transfusions. These complications include growth retardation, skeletal deformities, iron deposition in organs leading to organ damage (especially the heart, liver, and endocrine glands), and an increased risk of infections. To prevent iron overload and, in some cases, bone marrow transplantation, treatment involves supportive care, transfusion of blood or iron chelation. Ongoing research aims to develop novel therapies targeting the underlying molecular defects in beta-thalassemia.

Current Treatment Landscape [21-24]:

The multidisciplinary approach to management of beta thalassemia aims at alleviating symptoms, minimizing complications, and improving overall quality of life of patients

with beta thalassemia. Over the years, the treatment landscape for beta thalassemia has evolved significantly, with advances in supportive care and novel therapeutic approaches.

1. **Blood Transfusions**
   Regular blood transfusions represent the cornerstone of treatment for individuals with transfusion- dependent beta thalassemia, aiming to maintain hemoglobin levels and alleviate symptoms of anemia. Transfusions are typically administered every 2 to 4 weeks, depending on the patient's clinical status and hemoglobin levels. While effective in improving hemoglobin levels and relieving symptoms, frequent transfusions can lead to iron overload, a common complication of beta thalassemia therapy.
2. **Iron Chelation Therapy**
   Iron overload, resulting from chronic blood transfusions, poses a significant health risk for individuals with beta thalassemia. Excess iron accumulates in various organs and tissues, leading to organ damage, endocrine dysfunction, and cardiovascular complications. Iron chelation therapy, using agents such as deferoxamine, deferiprone, and deferasirox, helps mitigate the effects of iron overload by promoting the excretion of excess iron from the body. Long-term adherence to iron chelation therapy is essential to prevent irreversible organ damage and improve patient outcomes.
3. **Supportive Care Measures**
   In addition to blood transfusions and iron chelation therapy, individuals with beta thalassemia require comprehensive supportive care to address associated complications and optimize overall health. This may include nutritional supplementation, management of growth and development, treatment of skeletal abnormalities, and monitoring for endocrine dysfunction and cardiopulmonary complications. Multidisciplinary care teams, comprising hematologists, pediatricians, endocrinologists, cardiologists, and other specialists, collaborate to provide holistic care tailored to the individual needs of patients with beta thalassemia.
4. **Hematopoietic Stem Cell Transplantation (HSCT) [25-27]**
   Hematopoietic stem cell transplantation (HSCT) offers a potential cure for individuals with beta thalassemia, particularly in those with matched sibling donors. HSCT involves the infusion of healthy hematopoietic stem cells from a compatible donor, with the aim of restoring normal hematopoiesis and eliminating the need for lifelong transfusions. Successful outcomes depend on factors such as donor compatibility, patient age, disease severity, and the presence of comorbidities. HSCT carries risks of complications, including graft rejection, graft-versus-host disease, and transplant-related mortality, underscoring the importance of careful patient selection and comprehensive pre-transplant evaluation.
5. **Emerging Therapeutic Modalities [9,28-30]**
   Advancements in molecular biology and gene editing technologies have paved the way for innovative therapeutic approaches for beta thalassemia, including gene therapy and gene editing strategies.

Zynteglo (Lentiglobin), a pioneering gene therapy approved for transfusion-dependent beta thalassemia, represents a significant milestone in the field. Zynteglo involves the ex vivo modification of autologous hematopoietic stem cells using a lentiviral vector encoding a functional beta-globin gene, with the aim of restoring hemoglobin production and reducing or eliminating the need for chronic transfusions. Clinical trials have demonstrated promising results with Zynteglo, including sustained reductions in transfusion requirements and improvements in quality of life measures.

While significant progress has been made in improving outcomes and quality of life for individuals with beta thalassemia, challenges remain, including access to specialized care, financial barriers, and the need for long-term monitoring and follow-up. Continued research efforts and collaborative initiatives are essential to address these challenges and optimize treatment strategies for individuals living with beta thalassemia.

Zynteglo (Lentiglobin) Therapy [9,29,30]

Zynteglo, developed by Bluebird Bio, represents a groundbreaking therapeutic approach for transfusion-dependent beta thalassemia, offering the potential for long-term hematologic correction and reduced reliance on chronic blood transfusions. This innovative treatment, which provides hope to patients and families affected by beta thalassemia, is based on the power of gene therapy in addressing the underlying genetic defect responsible for this serious disease.

Beta thalassemia, a hereditary hemoglobin disorder which is characterized by reduced or absent synthesis of the beta globin chains of hemoglobin, is seen in a range of severity from asymptomatic carriers to life-threatening transfusion-dependent forms. People with transfusion-dependent beta thalassemia need ongoing blood transfusions to maintain their hemoglobin levels, leading to significant healthcare challenges and reduced quality of life. The accumulation of iron due to frequent transfusions worsens the health risks linked with the condition, highlighting the need for effective treatments to decrease its consequences.

Zynteglo therapy represents a paradigm shift in the management of transfusion-dependent beta thalassemia, offering the potential for durable therapeutic benefit and improved quality of life. The therapy involves a multi-step process that begins with the collection of autologous hematopoietic stem cells from the patient's bone marrow or peripheral blood. These stem cells serve as the foundation for the gene therapy procedure, possessing the capacity for self-renewal and differentiation into various blood cell lineages, including red blood cells.

Once harvested, the patient's hematopoietic stem cells undergo ex vivo modification using a lentiviral vector encoding a functional beta-globin gene. The lentiviral vector serves as a delivery vehicle, capable of efficiently integrating the therapeutic gene into the genome of the target cells [31]. This integration ensures stable and sustained expression of the beta-globin gene, facilitating the production of functional beta globin chains necessary for the formation of hemoglobin tetramers.

After gene transfer, the modified hematopoietic stem cells undergo a process called conditioning, wherein chemotherapy drugs are given to make space within the bone marrow and aid

in the acceptance of the gene-modified cells. This conditioning process temporarily suppresses the patient's current hematopoietic system, enabling the infused gene-modified cells to settle and replenish the bone marrow with healthy, genetically corrected cells.

After the conditioning process is complete, the gene-modified hematopoietic stem cells are reinfused into the patient's bloodstream. They migrate to the bone marrow and begin to proliferate and differentiate into mature blood cells, including red blood cells. Gradually, these genetically modified cells contribute to the production of functional hemoglobin, reducing the need for repeat blood transfusions and alleviating the symptoms associated with transfusion-dependent beta thalassemia.

Clinical trials evaluating Zynteglo have demonstrated promising results, with a significant proportion of patients achieving independence from chronic transfusions and sustained improvements in hemoglobin

levels. Moreover, patients treated with Zynteglo have reported improvement in quality of life measures, including decreased fatigue, improved exercise tolerance, and overall well-being.

The safety profile of Zynteglo has been carefully examined in clinical trials, with adverse events mainly linked to the conditioning regimen and stem cell transplantation process. Common side effects include cytopenias, infections, and gastrointestinal symptoms, which are typically manageable with supportive care measures and medical treatments.

Mechanism of Action [32-35]

The mechanism of action of Zynteglo (Lentiglobin) therapy for transfusion-dependent beta thalassemia involves a complex interaction of molecular biology, hematopoiesis, and genetic engineering.

Understanding the mechanisms underlying Zynteglo's therapeutic efficacy is essential for understanding its clinical significance and optimizing treatment strategies for patients with beta thalassemia.

Zynteglo therapy begins with the collection of autologous hematopoietic stem cells (HSCs) from the either the patient's bone marrow or peripheral blood. These HSCs serve as the cellular substrate for genetic modification, possessing the unique capacity for self-renewal and differentiate into multiple cell lineages. The extraction of patient-derived HSCs is a critical step in the Zynteglo treatment process, ensuring compatibility and decreasing the risk of immune rejection post-transplantation.

Following HSC collection, the cells undergo ex vivo genetic modification using a lentiviral vector that carries a functional beta-globin gene. Lentiviral vectors have emerged as versatile gene delivery vehicles, capable of efficiently delivering a wide range of target cells, including HSCs32,33. The lentiviral vector carrying the therapeutic beta-globin gene is carefully engineered to ensure stable integration into the genome of the target cells, facilitating sustained expression of the transgene and long-term therapeutic benefit.

The integration of the therapeutic beta-globin gene into the genome of the patient's HSCs is a crucial step in the Zynteglo treatment process. This integration occurs at specific genomic loci, guided by the properties of lentiviral vector and the cellular mechanisms responsible for DNA replication and repair.

The precise targeting and integration of the therapeutic gene helps reduce the risk of unintended effects and ensure the safe and effective delivery of the therapeutic gene.

Once integrated into target cells' genome, the therapeutic beta-globin gene becomes transcriptionally active, initiating the synthesis of functional beta globin chains. The introduction of the therapeutic beta- globin gene into the patient's HSCs restores the balance of alpha and beta globin chains, allowing the formation of functional hemoglobin tetramers. These tetramers have improved oxygen-carrying capacity and stability, alleviating the symptoms of anemia and reducing the need for chronic blood transfusions. By addressing the underlying genetic defect responsible for beta thalassemia, Zynteglo therapy offers the potential for sustained hematologic correction and improved quality of life for affected individuals.

The production of functional hemoglobin following Zynteglo therapy represents an impressive achievement of molecular engineering and cellular biology. The therapeutic benefits of Zynteglo extend beyond the correction of anemia, causing improvements in exercise tolerance, decrease in transfusion dependence, and enhancement of overall well-being. Clinical trials evaluating Zynteglo showed sustained improvements in hemoglobin levels and transfusion independence, highlighting the therapeutic potential of this innovative approach.

Eligibility Criteria [36,37]

The eligibility criteria for Zynteglo (Lentiglobin) therapy in patients with transfusion-dependent beta thalassemia are meticulously established to ensure optimal patient selection and treatment outcomes. While Zynteglo represents a promising therapeutic option for individuals with beta thalassemia, not all patients may meet the criteria for treatment initiation.

Candidates for Zynteglo therapy typically include individuals diagnosed with transfusion-dependent beta thalassemia who have demonstrated inadequate response to standard treatment modalities, such as regular blood transfusions and iron chelation therapy. These patients often experience complications associated with chronic transfusions, including iron overload, alloimmunization, and transfusion-related infections, emphasizing the need for alternative treatment approaches.

In addition to disease severity and treatment history, other factors may influence patient eligibility for Zynteglo therapy, such as age, underlying comorbidities, and disease-related complications. Pediatric and adult patients with transfusion-dependent beta thalassemia may be considered for Zynteglo therapy, provided they meet specific clinical and laboratory criteria and have the capacity to undergo the complex treatment process.

Comprehensive assessments are necessary to determine patient suitability for Zynteglo therapy and decrease potential risks

associated with treatment initiation. These evaluations may include hematologic assessments, genetic testing, cardiac evaluations, and psychosocial assessments. The aim is to ensure that patients are well-prepared for the treatment process and understand the potential benefits and risks of therapy.

Patients with contraindications to hematopoietic stem cell transplantation or significant medical comorbidities that may impact treatment outcomes should be excluded from consideration for Zynteglo therapy. Additionally, patients with active infections or uncontrolled medical conditions may require optimization of their clinical status before undergoing treatment initiation.

The decision to pursue Zynteglo therapy should be made in close collaboration with a multidisciplinary team of healthcare professionals, including hematologists, genetic counselors, transplant specialists, and supportive care providers. Patient preferences, goals of care, and expectations should be carefully considered during the treatment decision-making process to ensure informed consent and shared decision-making.

Clinical Efficacy and Safety [9,35,37,38]

Clinical trials evaluating the efficacy and safety of Zynteglo (Lentiglobin) therapy in patients with transfusion-dependent beta thalassemia have produced encouraging results, highlighting the therapeutic potential of this innovative treatment approach. These trials have provided valuable insights into the long-term hematologic responses, transfusion requirements, and safety profile of Zynteglo therapy, facilitating it's incorporation into clinical practice and treatment decision-making for patients with beta thalassemia.

Studies evaluating Zynteglo therapy have demonstrated sustained improvements in hemoglobin levels and reductions in transfusion requirements among treated patients. Many individuals treated with Zynteglo have achieved transfusion independence or experienced significant reductions in the frequency and volume of blood transfusions required to maintain hemoglobin levels. These improvements in transfusion requirements have led to better quality of life, including reduced fatigue, improved exercise tolerance, and decreased healthcare burden associated with chronic transfusions.

Moreover, Zynteglo therapy has been associated with improvements in disease-related complications, including reductions in iron overload and the need for iron chelation therapy. By targeting the underlying genetic defect responsible for beta thalassemia, Zynteglo therapy offers the potential for long-lasting hematologic correction and decreasing disease-related morbidity and mortality.

The safety profile of Zynteglo therapy has been carefully evaluated in clinical trials, with adverse events primarily related to the conditioning regimen and stem cell transplantation process. Common side effects include cytopenias, infections, and gastrointestinal symptoms, which are typically manageable with supportive care measures and medical interventions. Serious adverse events, such as graft failure or graft-versus-host disease, have been reported in a small subset of patients, highlighting the importance of post-treatment surveillance.

Conclusion

In conclusion, Zynteglo (Lentiglobin) therapy represents a novel treatment approach for individuals with transfusion-dependent beta thalassemia, offering the potential for long-lasting hematologic correction and improved quality of life. By addressing the underlying genetic defect responsible for beta thalassemia, Zynteglo therapy aims to reduce or eliminate the need for chronic blood transfusions and decrease disease-related complications, including iron overload and end-organ damage.

Clinical trials evaluating Zynteglo therapy have demonstrated promising results, with many patients achieving transfusion independence and sustained improvements in hemoglobin levels. Furthermore, Zynteglo therapy has been associated with reductions in disease-related complications and improvement in quality of life measures, highlighting its therapeutic potential and clinical utility in the management of beta thalassemia.

Long-term follow-up studies are ongoing to assess the durability of therapeutic responses, monitor for potential late adverse effects, and optimize treatment protocols for Zynteglo therapy. Additionally, efforts are underway to expand access to Zynteglo therapy and address logistical and regulatory challenges associated with its implementation in clinical practice.

The introduction of Zynteglo therapy marks a new era in the management of transfusion-dependent beta thalassemia, offering hope and promise to patients and families affected by this challenging hematologic disorder. By advancing our understanding of the molecular mechanisms of underlying beta thalassemia and Zynteglo therapy, we can establish the foundation for future innovations in the treatment of genetic diseases and improve outcomes for patients worldwide.

In summary, Zynteglo therapy represents a significant advancement in the field of hematology and gene therapy, offering a curative treatment option for individuals affected with transfusion-dependent beta thalassemia. Through ongoing research, collaboration, and innovation, Zynteglo has the potential to revolutionize the treatment landscape for beta thalassemia and transform the lives of patients living with this debilitating condition.

Financial interest statement: "The authors declare that they have no relevant or material financial interests that relate to the research described in this paper."

Conflicts of interest: The authors have no conflict of interest.

References

1. Sayani FA, Kwiatkowski JL. Increasing prevalence of thalassemia in America: Implications for primary care. Ann Med 2015. 47: 592-604.
2. Nienhuis AW, Nathan DG. Pathophysiology and Clinical Manifestations of the beta-Thalassemias. Cold Spring Harb Perspect Med 2012. 2: a011726.
3. Sanchez-Villalobos M, Blanquer M, Moraleda JM, Salido EJ, Perez-Oliva AB. New Insights Into Pathophysiology of beta-Thalassemia. Front Med (Lausanne) 2022. 9: 880752.
4. Wickramasinghe SN, Hughes M. Ultrastructural studies of erythropoiesis in beta-thalassaemia trait. Br J Haematol 1980. 46: 401-7.

5. Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009. 84: 29-33.
6. Li J, Wang P, Li X, Wang Q, Zhang J, et al. Cost-Utility Analysis of four Chelation Regimens for beta-thalassemia Major: a Chinese Perspective. Mediterr J Hematol Infect Dis. 2020. 12: e2020029.
7. Paramore C, Vlahiotis A, Moynihan M, Cappell K, Ramirez-Santiago A. Treatment Patterns and Costs of Transfusion and Chelation in Commercially-Insured and Medicaid Patients with Transfusion-Dependent β-Thalassemia. Blood 2017. 130: 5635.
8. Yousuf R, Akter S, Wasek SM, Sinha S, Ahmad R, et al. Thalassemia: A Review of the Challenges to the Families and Caregivers. Cureus 2022. 14: e32491.
9. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype beta-Thalassemia. N Engl J Med 2022. 386: 415-427.
10. Taher AT, Bou-Fakhredin R, Kattamis A, Viprakasit V, Cappellini MD. Improving outcomes and quality of life for patients with transfusion-dependent beta-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Rev Hematol. 2021. 14: 897-909.
11. Cring MR, Sheffield VC. Gene therapy and gene correction: targets, progress, and challenges for treating human diseases. Gene Ther 2022. 29: 3-12.
12. Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of beta- thalassemia. Eur J Haematol 2020. 105: 692-703.
13. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008. 86: 480-7.
14. Hulihan MM, Feuchtbaum L, Jordan L, et al. State-based surveillance for selected hemoglobinopathies. Genet Med 2015. 17: 125-30.
15. Premawardhana AP, Mudiyanse R, De Silva ST, et al. A nationwide survey of hospital-based thalassemia patients and standards of care and a preliminary assessment of the national prevention program in Sri Lanka. PLoS One 2019. 14: e0220852.
16. El-Beshlawy A, Dewedar H, Hindawi S, et al. Management of transfusion-dependent β- thalassemia (TDT): Expert insights and practical overview from the Middle East. Blood Reviews 2024. 63: 101138.
17. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010. 5: 11.
18. Weatherall D. 2003 William Allan Award address. The Thalassemias: the role of molecular genetics in an evolving global health problem. Am J Hum Genet 2004. 74: 385 -92.
19. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013. 98: 833-44.
20. Cao A, Galanello R. Beta-thalassemia. Genet Med 2010. 12: 61-76.
21. Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, et al. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere 2022. 6: e732.
22. Pinto VM, Forni GL. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series. Int J Mol Sci 2020. 21.
23. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program 2017. 2017: 265-271.
24. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011. 118: 3479 -88.
25. Caocci G, Orofino MG, Vacca A, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol 2017. 92: 1303-1310.
26. Khaddour K, Hana CK, Mewawalla P. Hematopoietic Stem Cell Transplantation. StatPearls. Treasure Island (FL)2024.
27. Lucarelli G, Isgro A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med 2012. 2: a011825.
28. Christakopoulos GE, Telange R, Yen J, Weiss MJ. Gene Therapy and Gene Editing for beta- Thalassemia. Hematol Oncol Clin North Am 2023. 37: 433-447.
29. Segura EER, Ayoub PG, Hart KL, Kohn DB. Gene Therapy for beta-Hemoglobinopathies: From Discovery to Clinical Trials. Viruses 2023. 15.
30. Asghar AA, Khabir Y, Hashmi MR. Zynteglo: Betibeglogene autotemcel - An innovative therapy for beta- thalassemia patients. Ann Med Surg (Lond) 2022. 82: 104624.
31. Morgan RA, Gray D, Lomova A, Kohn DB. Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. Cell Stem Cell 2017. 21: 574-590.
32. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 2011. 12: 51-8.
33. Magrin E, Miccio A, Cavazzana M. Lentiviral and genome-editing strategies for the treatment of beta-hemoglobinopathies. Blood 2019. 134: 1203-1213.
34. Cavazzana M, Antoniani C, Miccio A. Gene Therapy for beta-Hemoglobinopathies. Mol Ther 2017. 25: 1142-1154.
35. Marktel S, Scaramuzza S, Cicalese MP, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ss-thalassemia. Nat Med 2019. 25: 234-241.
36. Baronciani D, Casale M, De Franceschi L, et al. Selecting beta-thalassemia Patients for Gene Therapy: A Decision-making Algorithm. Hemasphere 2021. 5: e555.
37. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene Therapy in Patients with Transfusion- Dependent beta-Thalassemia. N Engl J Med 2018. 378: 1479-1493.
38. Boulad F, Maggio A, Wang X, et al. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with beta-thalassemia: a phase 1 trial. Nat Med 2022. 28: 63-70.